EXPERIMENTAL STUDY

Maternal glucocorticoid treatment modulates placental leptin and leptin receptor expression and materno–fetal leptin physiology during late pregnancy, and elicits hypertension associated with hyperleptinaemia in the early-growth-retarded adult offspring

Mary C Sugden, Maria L Langdown, Melinda J Munns and Mark J Holness

Department of Diabetes and Metabolic Medicine, Division of General and Developmental Medicine, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, London, UK

(Correspondence should be addressed to M J Holness, Department of Diabetes and Metabolic Medicine, Medical Sciences Building, Queen Mary, University of London, Mile End Road, London E1 4NS, UK; Email: m.j.holness@qmw.ac.uk)

Abstract

Background: Leptin concentrations are increased during late pregnancy, and leptin receptors are expressed in placental and fetal tissues, suggesting a role for leptin in placental and/or fetal growth, or both. In humans, leptin concentrations in adulthood are inversely related to body weight at birth, independent of adult adiposity, and correlate with fasting insulin. Glucocorticoids and insulin regulate leptin secretion. Excessive exposure to glucocorticoids during late fetal development in the rat causes intrauterine growth retardation (IUGR), together with hypertension and hyperinsulinaemia in adulthood. Leptin may have a role in the development of some forms of hypertension.

Objective: To determine whether IUGR induced by maternal glucocorticoid treatment during the last third of pregnancy in the rat is associated with modulation of either maternal or fetal leptin concentrations, the placental expression of leptin or the short form of the leptin receptor (ObR-S), or combinations thereof, and to evaluate whether hypertension or hyperinsulinaemia in the early-growth-retarded adult progeny of dexamethasone-treated dams is associated with altered leptin concentrations.

Design and Methods: Dexamethasone was administered to pregnant rats from day 15 to day 21 of gestation via a chronically implanted subcutaneous osmotic minipump. Protein expression of leptin and ObR-S in the placenta at day 21 of pregnancy was measured by western blotting. Plasma leptin and insulin concentrations were determined by radioimmunoassay and ELISA respectively. Systolic hypertension was measured by tail cuff plethysmography.

Results: Dexamethasone administration during the last third of pregnancy decreased placental mass and fetal body weight at day 21 of gestation, caused maternal hyperleptinaemia but fetal hypoleptinaemia, and suppressed placental leptin protein expression whilst up-regulating placental protein expression of ObR-S. The male and female offspring of dexamethasone-treated dams were hypertensive from 12 weeks of age. One-year-old offspring of dexamethasone-treated dams exhibited significant hyperleptinaemia compared with age-matched controls, an effect associated with hyperinsulinaemia in the male, but not female, offspring.

Conclusions: The rat model of maternal dexamethasone treatment is established as a paradigm of ‘programmed’ hypertension in man. Our data show modification of placental leptin and leptin receptor protein expression by dexamethasone treatment during the last third of pregnancy. We also show that leptin concentrations are suppressed during fetal life but increased in adulthood in this rat model of programmed hypertension. Our data do not necessarily establish a causal relationship between fetal hypleptinaemia and impaired fetal growth during early life, or between hyperleptinaemia and hypertension in adulthood. Nevertheless, they suggest that hyperleptinaemia may be a component of the cluster of metabolic abnormalities seen in the insulin resistance syndrome in man. They also suggest that excessive fetal exposure to glucocorticoids could be a common early-life stimulus to the association between hyperinsulinaemia, hypertension and hyperleptinaemia often seen in individuals of low birthweight.
Introduction

Leptin acts as an afferent satiety hormone, regulating appetite, body weight gain and fat deposition (1, 2; reviewed in 3) via a negative feedback loop involving receptors in the hypothalamus (2, 4). In addition, increased circulating concentrations of leptin are found during late pregnancy both in women and in animal models. In humans, plasma leptin concentrations are increased significantly (by approximately 2.7-fold) during the second trimester of pregnancy and remain high during the third trimester, decreasing around birth (5, 6). Comparable increases in maternal leptin concentrations are observed in the rat, in which maternal plasma leptin concentrations during late pregnancy are increased by approximately twofold compared with those found in the non-pregnant state (7). In the mouse, the animal model most frequently used for studies of the potential roles of leptin during pregnancy, leptin concentrations in the maternal circulation increase even more dramatically (25-fold) during late pregnancy (8). Findings of increased leptin concentrations during late pregnancy (5, 6, 9) and the expression of leptin receptors in a range of fetal tissues (10) have raised the possibility that increased leptin concentrations during pregnancy perform a physiological function.

Leptin protein concentrations in human umbilical cord blood positively correlate with body weight and adiposity at birth, suggesting a potential role in fetal and adipose tissue development (11–14). However, leptin replacement therapy has permitted successful matings between ob/ob female mice and ob/ob males (15), and leptin withdrawal at various stages of the pregnancy does not appear to influence offspring growth and viability (16). Such findings indicate that high maternal leptin concentrations are not vital for fetal development and argue against an obligatory role for leptin in modulating fetal growth. However, several of six alternatively spliced forms of mRNA for the leptin receptor (ObR) have been identified in the mouse placenta. These include the short form of the leptin receptor, ObR-S (the proposed transport form of the receptor) (10, 17), and the long form of the leptin receptor, ObR-L (the proposed signalling form of the leptin receptor) (18). In human pregnancies, maternal plasma leptin concentrations negatively correlate with placental weight at term (11). The possibility is therefore raised that leptin could influence placental growth and development or function, or both.

Although the precise role of leptin as a fetal growth factor remains unresolved, two independent studies have shown that blood concentrations of leptin in adulthood are the opposite of the reported positive correlations seen between body weight and leptin production in fetuses (21) and infants (11–14). Maternal nutrition during pregnancy influences the body weight of the fetus (22–24) and, in female pigs, plasma leptin concentrations are higher in progeny from mothers provided with more feed (25). In this last study, although maternal nutrition did not affect mean body weight at birth, there was a negative relationship between body weight at birth and measures of leptin production in adulthood (25). Hormonal influences may also be important. Glucocorticoids have an important role in normal fetal development and, in many instances, are important for the maturation of fetal tissues in preparation for extra-uterine life (reviewed in 26). However, fetal exposure to excess glucocorticoids has been implicated as a causative factor in fetal growth retardation (reviewed in 27, 28). Moreover, fetal cortisol concentrations are increased in human intrauterine growth retardation (29). The influence of glucocorticoids on maternal and fetal leptin concentrations in relation to fetal growth retardation is unknown.

The fetus is normally protected from the higher maternal concentrations of glucocorticoids by the placental enzyme 11 β-hydroxysteroid dehydrogenase type-2 (11 β-HSD-2), which is highly expressed in the placental syncytiotrophoblast (30) and catalyses the rapid conversion of active glucocorticoids to inert 11-keto derivatives (i.e. cortisol to cortisone in humans and corticosterone to 11 dehydrocorticosterone in rats). The synthetic glucocorticoid dexamethasone is a poor substrate for 11β-HSD-2 (30, 31) and, in the rat, dexamethasone administration during the last third of pregnancy leads to fetal growth retardation (reviewed in 27, 28). Early growth retardation induced by maternal dexamethasone treatment produces fasting and post-glucose hyperinsulinaemia (32) and hypertension (33) in the adult offspring. Hyperinsulinaemia is often associated with hyperleptinaemia (34–37). Emerging evidence suggests a physiological role for leptin in maintaining arterial blood pressure (38). Furthermore, blood pressure is increased in transgenic skinny mice and obese KKA® mice, both of which are hyperleptinaemic (39). In man, increased leptin concentrations have been suggested to contribute to the aetiology of essential hypertension (40). In the present study, we tested the hypothesis that the intrauterine growth retardation induced by maternal glucocorticoid treatment during the last third of pregnancy in the rat might be associated with modulation of either maternal or fetal leptin concentrations or the placental expression of leptin or ObR-S, and whether the effect of maternal dexamethasone treatment to programme hypertension and hyperinsulinaemia in the adult progeny is associated with modulation of plasma leptin concentrations.
Materials and methods

Materials

Female Wistar rats were obtained from Charles River Ltd, Margate, Kent, UK. All organic solvents were of analytical grade and obtained from BDH Laboratories Supplies, Poole, Dorset, UK. Other biochemicals and chemicals, including glucose assay kits, were from Boehringer Corporation, Lewes, East Sussex, UK or from Sigma Chemical Corporation, Poole, Dorset, UK, with the following exceptions. Plasma leptin was measured using kits from Linco Research, St Louis, MO, USA. Kits for determination of plasma insulin concentrations by ELISA were from Mercodia, Uppsala, Sweden. Reagents for enhanced chemiluminescence (ECL) detection and anti-rabbit secondary antibody were purchased from Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK. Anti-leptin (Y-20, Santa Cruz Biotechnology) rabbit polyclonal antibody, anti-ObR (K-20, Santa Cruz Biotechnology), goat polyclonal antibody and anti-goat secondary antibody were purchased from Insight Biotechnology Ltd (Wembley, Middx., UK). Dexamethasone (sodium phosphate) was obtained from David Bull Laboratories, Warwick, Warwickshire, UK. Mini-osmotic pumps were purchased from Charles River Ltd, Margate, Kent, UK

Animals

All studies were conducted in adherence to the regulation of the United Kingdom Animal Scientific Procedures Act (1986). Female Wistar rats weighing 200–250 g were subjected to a standard light (0800–2000 h)–darkness (2000–0800 h) cycle in a temperature-controlled room (21 ± 2°C). The rats were housed in individual cages and were given free access to food and water. Rats were maintained on standard, pelleted rodent diet. Male and female offspring of control and dexamethasone-treated dams were separated at 26 days after birth, and the offspring weaned on to standard, pelleted rodent diet. Male and female offspring of control and dexamethasone-treated dams were studied at intervals up to 1 year of age. Each data group was comprised of rats from at least three separate litters. In total, 12 offspring of control dams and eight offspring of dexamethasone-treated dams were studied.

Tissue and blood sampling

Rats were anaesthetised by intraperitoneal injection of sodium pentobarbitone (60 mg/ml in 0.9% NaCl; 1 ml/kg body weight). Once locomotor activity had ceased, three whole placentas from individual animals were rapidly excised. Amniotic membranes were removed and placentas were freeze-clamped in liquid nitrogen using precooled aluminium tongs. Frozen placental samples were wrapped individually in aluminium foil and stored in liquid nitrogen. Plasma was obtained from whole blood sampled from the chest cavity after the removal of the heart, and stored at −20 °C until required for analysis.
Western blotting

Placental samples (approximately 100 mg) were homogenised using a Polytron Tissue homogeniser (PT 10 probe; position 5, 15 s) in 1 ml ice-cold extraction buffer A: 20 mM Tris, 137 mM NaCl, 2.7 mM KCl, 1 mM CaCl2, 10% glycerol, 1% Igepal, 45 mM sodium orthovanadate (Na3VO4), 0.2 mM phenyl methylsulphonyl fluoride, 10 μg/ml leupeptin, 1.5 mg/ml benzamidine, 50 μg/ml aprotinin. 50 μg/ml pepstatin A (in DMSO), pH 8.0. Homogenates were placed on ice for 20 min, centrifuged in an Eppendorf centrifuge (12 000 r.p.m. for 20 min. at 4°C) and the supernatants stored at −20°C until required for analysis. Samples (20–30 μg of total protein) were subjected to SDS-PAGE using a 12% (leptin) or 9% (leptin receptor) resolving gel, with a 6% stacking gel. After SDS-electrophoresis, resolved proteins were transferred electrophoretically to nitrocellulose membranes, and then blocked for 2 h at room temperature (Tris-buffered saline (TBS) supplemented with 0.05% Tween (TBST) and 5% (w/v) non-fat powdered milk). The nitrocellulose blots were incubated overnight at 4°C with polyclonal antisera against leptin or the leptin receptor (1:200) in 5% (w/v) non-fat powdered milk. Bound antibody was visualised using ECL according to the manufacturer’s instructions. The blots were then exposed to Hyperfilm and the signals quantified by scanning densitometry and analysed with Molecular Analyst software (Biorad Ltd, Hemel Hempstead, Herts, UK). An initial characterisation using competing antigenic peptides was performed to determine the specificity of the antibodies. The specific protein bands corresponding to the proteins were linear with concentration. Immunoblots were performed under conditions in which autoradiographic detection was in the linear response range. For each panel, the results are from a single gel exposed for a uniform duration.

Biochemical and physiological determinations

Plasma insulin concentrations were measured by ELISA using rat insulin standards (Mercodia). Plasma leptin concentrations were determined by a commercially available RIA using rat leptin standards (Rat Leptin RIA Kit, Linco Research). Systolic blood pressures were determined by tail cuff plethysmography at room temperature in lightly anaesthetised rats (sodium pentobarbionate; 100 μg/300 g body weight). All measurements were taken in the morning and each rat had five blood pressure traces recorded in a single session. The coefficient of variation was 3.2%.

Statistical analyses

Statistical comparisons were made with StatView (Abacus Concepts Inc., Berkeley, CA, USA). Multiple comparisons were made by analysis of variance (ANOVA) and individual comparisons by Fisher post hoc tests. Comparisons between just two sets of data were performed with the unpaired Student’s t-test. The criterion for significance was set at P < 0.05. All data are presented as the means ± S.E.M.

Results

Maternal dexamethasone treatment during pregnancy in the rat decreases maternal body weight without influencing maternal food intake

Maternal dexamethasone administration at a dose of either 100 or 200 μg/kg body weight during the last third of pregnancy (from day 15) led to a 17% (P < 0.05) or 23% (P < 0.01) decrease in maternal body weight at day 21 of gestation (Fig. 1A). Dexamethasone administration did not alter duration of gestation or the number or viability of offspring (results not shown). No further decline in maternal body weight at day 21 of pregnancy or the number or viability of offspring (results not shown). No further decline in maternal body weight at day 21 of pregnancy or the number or viability of offspring (results not shown). No further decline in maternal body weight at day 21 of pregnancy or the number or viability of offspring (results not shown).
weight occurred when the dexamethasone dose was increased to 400 μg/kg maternal body weight, but offspring viability decreased (results not shown). This procedure was therefore discontinued. Suppression of maternal body weight by dexamethasone administration occurred in the absence of any marked decline in maternal food intake relative to control; the normal decline in maternal food intake occurring during the last few days of pregnancy (term = 23 days) was observed in all three groups (Fig. 1B).

**Maternal dexamethasone treatment during pregnancy in the rat impairs fetal growth**

We confirmed that prenatal exposure to dexamethasone leads to fetal intrauterine growth retardation, as reported previously when dexamethasone was administered daily as a bolus (42). The effect of maternal dexamethasone administration was dose dependent. As seen in Fig. 2A, maternal dexamethasone administration at a dose of 100 or 200 μg/kg body weight from day 15 of gestation led respectively to an 8.9% (P < 0.01) and a 28.7% (P < 0.001) decrease in fetal body weight at day 21 of gestation.

**Maternal dexamethasone treatment during late pregnancy in the rat decreases placental weights**

Placental weight at day 21 of gestation was also significantly decreased in a dose dependent manner by dexamethasone treatment from day 15 of gestation (Fig. 2B). Placental weight was decreased by 27% (P < 0.05) at the lower dexamethasone dose (100 μg/kg body weight) and by 45% (P < 0.05) at the higher dose (200 μg/kg body weight). Thus the percentage decline in placental weight (when expressed relative to the percentage decline in fetal body weight) was independent of dexamethasone dose but, irrespective of dose, exceeded that of the fetus.

**Maternal leptin concentrations are increased in a dose-dependent manner by dexamethasone administration**

Maternal plasma leptin concentrations at day 21 of gestation tended to be greater (by 1.6-fold) in the pregnant group treated with dexamethasone at 100 μg/100 g body weight, and were significantly higher (by 3.9-fold, P < 0.01) as a result of dexamethasone treatment at the higher dose (Fig. 3A). The increases in circulating leptin concentrations were observed in the absence of increases in adipose tissue mass, assessed by visual inspection. In a limited number of further experiments, we observed that increasing the dexamethasone dose to 400 μg/kg body weight massively increased maternal leptin concentrations (to 28.5±2.5 ng/ml; n = 2), but these experiments were discontinued because of poor tolerance (see above).

**Fetal leptin concentrations are suppressed by maternal dexamethasone treatment**

Fetal plasma leptin concentrations were considerably lower than those of the dams (note change of scale)

---

**Figure 2** Fetal and placental weights of 21-day-old control pregnant rats (CON; open bars) and 21-day-old pregnant rats administered dexamethasone at doses of 100 μg/kg maternal body weight per day (DEX 100; latticed bars) or 200 μg/kg maternal body weight per day (DEX 200; hatched bars) from day 15 of pregnancy. Results are presented as means ± S.E.M. for five to seven rats (dams) or four litters (fetuses). Statistically significant effects of maternal dexamethasone administration: *P < 0.05; **P < 0.01; ***P < 0.001.

**Figure 3** Maternal and fetal circulating leptin concentrations of 21-day-old control pregnant rats (CON; open bars) and 21-day-old pregnant rats administered dexamethasone at a dose of 100 μg/kg maternal body weight per day (DEX 100; latticed bars) or 200 μg/kg maternal body weight per day (DEX 200; hatched bars) from day 15 of pregnancy. Results are presented as means ± S.E.M. for five to seven rats (dams) or four litters (fetuses). Statistically significant effects of maternal dexamethasone administration: **P < 0.01.
and, contrasting with the maternal response, were decreased in a dose-dependent manner by maternal dexamethasone treatment (Fig. 3B) and achieved significance at the higher dexamethasone dose (46% decline, *P* < 0.01).

Maternal dexamethasone treatment during pregnancy in the rat down-regulates placental leptin expression at day 21 of gestation

In control rats, placental leptin was immunodetectable as a band corresponding to 16 kDa (Fig. 4). Placental leptin protein expression in late pregnancy (day 21) was significantly decreased (by 47%, *P* < 0.01) by maternal dexamethasone treatment at a dose of 100 μg/kg body weight. Increasing the dose to 200 μg/kg body weight per day did not further suppress placental leptin protein expression.

Protein expression of ObR-S is up-regulated by maternal dexamethasone treatment in the 21-day-old placenta

We also analysed the effect of dexamethasone on the placental protein expression of ObR-S in the 21-day-old pregnant rat. By western blotting, we detected an immunoreactive band at approximately 118 kDa using the short-form specific (ObR K-20, Santa Cruz Biotechnology) leptin receptor antibody (see also (43)). This was the only major band detected. Although dexamethasone at the lower dose did not significantly influence placental ObR-S protein expression at day 21 of gestation, dexamethasone at a dose of 200 μg/kg maternal body weight selectively up-regulated placental ObR-S (36%, *P* < 0.05) (Fig. 4B).

Maternal dexamethasone treatment during pregnancy leads to hypertension in adulthood

In control offspring, systolic blood pressure increased with age in both male and female groups, but effects of ageing to increase systolic blood pressure were greater in the male group (results not shown). Systolic blood pressure was significantly higher in offspring of dexamethasone-treated dams compared with control offspring at 3 months of age in both male and female offspring (+26% and +25% respectively; *P* < 0.05). This effect persisted at 6 months of age in both male and female offspring (+25% and +15% respectively; *P* < 0.05). Systolic blood pressures at 1 year of age are shown in Fig. 5. Both male and female offspring of dexamethasone-treated dams exhibited significant systolic hypertension compared with control offspring (*P* < 0.01 and *P* < 0.001 respectively).

Maternal dexamethasone treatment during pregnancy leads to hyperleptinaemia in adult (1-year-old) offspring

In control offspring, plasma leptin concentrations increased with age in both male and female groups,
but effects of ageing in increasing plasma leptin concentrations were greater in the male group. As a consequence, plasma leptin concentrations tended to be greater in the rats at 3 months of age and were 3.2-fold higher (P < 0.05) at 6 months of age in male than in female control offspring. In rats at 1 year of age, plasma leptin concentrations were 2.3-fold (P < 0.01) greater in male than in female control offspring (Fig. 6A). Leptin concentrations did not differ significantly between control offspring and offspring of dexamethasone-treated dams at any of the time points examined up to 6 months of age. However, by 1 year of age, both male and female offspring of dexamethasone-treated dams exhibited increased plasma leptin concentrations compared with control offspring (1.6- and 2.3-fold increases respectively; P < 0.05 in both cases) (Fig. 6A). Measurement of adipose tissue weights of representative depots of male (epidydymal) and female (parametrial) control offspring and offspring of dexamethasone-treated dams indicated that hyperleptinaemia in male and female offspring of dexamethasone-treated dams was not a consequence of increased adiposity. Epidydymal adipose tissue fat mass of male rats was significantly decreased (by 59%; P < 0.001) in offspring of dexamethasone-treated dams (control, 7.4 ± 0.5 g; dexamethasone, 3.1 ± 0.7 g), whereas parametrial fat mass of female rats did not differ significantly between control offspring and offspring of dexamethasone-treated dams (control, 3.9 ± 0.5 g; dexamethasone, 3.0 ± 0.3 g).

**Maternal dexamethasone treatment during pregnancy increases ambient plasma insulin concentrations in male offspring during maturation and in adulthood**

There were no obvious sex differences in plasma insulin concentrations during the first 3 months of post-natal life in either control offspring or offspring of dexamethasone-treated dams. However, by 6 months of age plasma insulin concentrations were significantly greater in the male than in female control offspring (by 1.6-fold; P < 0.05) and offspring of dexamethasone-treated dams (by 1.7-fold; P < 0.01). In addition, the male offspring of dexamethasone-treated dams had developed significant ambient hyperinsulinemia, compared with age-matched control offspring, by 6 months of age (by 2.1-fold; P < 0.001). In female offspring of dexamethasone-treated dams, plasma insulin concentrations were also significantly increased (1.9-fold; P < 0.05) compared with age-matched controls by 6 months of age. At 1 year of age, plasma insulin concentrations were significantly higher (by 3.7-fold; P < 0.001) in the male versus female offspring of dexamethasone-treated dams, but not in control offspring (Fig. 6B). The male offspring of dexamethasone-treated dams maintained significant ambient hyperinsulinemia, compared with age-matched control offspring, at 1 year of age (by 1.6-fold; P < 0.05), but this effect was no longer observed in female offspring of dexamethasone-treated dams at 1 year of age (Fig. 6B).

**Discussion**

This study has demonstrated that the fetal growth retardation elicited by dexamethasone administration during the last third of pregnancy in the rat is associated with decreased placental mass and fetal body weight at day 21 of gestation, together with maternal hyperleptinaemia but fetal hypoleptinaemia, and suppression of placental leptin protein expression in the face of modest up-regulation of placental ObR-S protein expression. Dexamethasone administration during the last third of pregnancy led to hypertension in the adult progeny, which was significant from 12 weeks of age and observed in both male and female offspring. It also resulted in significant hyperleptinaemia in 1-year-old male and female offspring, an effect associated with hyperinsulinemia in the 1-year-old male, but not female, offspring of dexamethasone-treated dams.

The present study demonstrates that maternal leptin concentrations at day 21 of pregnancy are up-regulated in a dose-dependent manner by chronic exposure to dexamethasone for the preceding 7 days. Increased leptin concentrations are not associated with a decreased daily food intake by the dexamethasone-treated dams compared with control. This suggests that, within the context of mid-to-late pregnancy, a decline (rather than an increase) in leptin concentrations is the primary regulatory stimulus for modulation
of appetite (i.e., satiety mechanisms respond to changes in leptin concentrations in the low physiological range). The present study does not, however, exclude the possibility that dexamethasone inhibits the ability of leptin to signal satiety (44) or that pregnancy is a ‘leptin resistant’ state with respect to appetite control (3, 16). Increased plasma leptin concentrations evoked by maternal dexamethasone treatment were associated with complete abrogation of maternal body weight gain during the last third of pregnancy. Visual inspection of the dams at the time of sampling suggested a decline in maternal fat mass (although this was not quantified). The present experiments do not indicate whether impaired weight gain was a direct action of dexamethasone or of changes secondary to effects of dexamethasone. However, impaired weight gain was apparent even at the lowest dexamethasone dose at which maternal leptin concentrations were only slightly increased, suggesting that leptin itself is not responsible.

In the non-pregnant state, adipose tissue is the major site of leptin production (1, 45) and leptin concentrations correlate with body mass index (46). However, leptin concentrations during pregnancy are increased to an extent that cannot be attributed to an increased body mass index (5, 9). Northern and western analysis have demonstrated leptin mRNA and leptin protein in placentas from a wide range of species, despite the different forms of placentation (10, 47), highlighting the possibility that the placenta might contribute to leptin production during pregnancy. In pregnant women, leptin is synthesised in and secreted from placental trophoblasts into the maternal and feto–placental circulation (48). Moreover, studies with cultured human placenta cells, WSH (amnion) and JEG3 (trophoblast) cells, have shown effects of dexamethasone to increase leptin production by more than twofold (49). In contrast, some studies have failed to detect the presence of leptin in the rat placenta (8) and in rodents, unlike humans, the placenta may not be the major source of maternal leptin production (7). Indeed, in mice, hyperleptinaemia during pregnancy primarily results from corticosterone-dependent up-regulation of leptin secretion from adipose tissue (50). The present study demonstrated protein expression of leptin and ObR-S in the rat placenta near term (day 21, term is 23 days) and demonstrates that placental leptin expression is responsive to glucocorticoid status. It has been suggested that a decrease in fetal nutrient availability towards term may result in a decrease in placental leptin production, in conjunction with an increase in fetal cortisol secretion, thereby leading to the onset of parturition (51). Our data suggest that the glucocorticoid surge characteristic of late gestation may also down-regulate placental leptin production. Taken together, the data suggest that changes in either fetal or maternal leptin may be important for parturition or late fetal development. As the administration of dexamethasone during the last third of pregnancy produced a significant decrease (rather than an increase) in placental leptin expression, our findings would suggest either that leptin secretion from adipose tissue or leptin transport from the placenta is enhanced by glucocorticoids in late pregnancy.

Interestingly, although changes in maternal plasma leptin concentrations do not correlate positively with changes in placental leptin protein expression, placental weight is negatively related to maternal plasma leptin concentrations. Maternal plasma leptin concentrations have been shown previously to correlate negatively with placental weight at term in human pregnancies (11). Pregnancies complicated with intrauterine growth restriction are often associated with increased placental apoptosis (52). The present experiments suggest that a common stimulus to leptin secretion and placental apoptosis may be inappropriately increased maternal glucocorticoid concentrations. Leptin stimulates placental angiogenesis in primary cultures of human endothelial cells (53) and may have a local autocrine immunomodulatory or anti-inflammatory role (54). In view of the finding of leptin receptor protein expression in the rat placenta during late pregnancy, it is not excluded that suppression of placental leptin expression may be a mechanism by which increased glucocorticoids influence placental size through augmenting placental degeneration.

Leptin has been implicated as a potentially important new growth factor in intrauterine and neonatal development (55). Concentrations of leptin in placental and cord blood are often decreased in pregnancies complicated by fetal growth retardation, and increased in those complicated with maternal diabetes (56). In a 33-week twin pregnancy in which one twin was growth retarded and the other a normal size, leptin concentrations in cord blood were lower with the growth-retarded fetus (56). However, it is still not known whether leptin directly regulates fetal growth. In our study, fetal plasma leptin concentrations correlated positively with fetal weights at day 21 of pregnancy. This is consistent with the possibility that fetal leptin acts as a fetal growth factor, and the concept that a ‘threshold’ level of leptin may be required for optimal fetal growth during normal pregnancy in the rat. Alternatively, factors influencing fetal growth, including glucocorticoids, have a direct effect to regulate fetal leptin concentrations but fetal leptin concentrations themselves do not regulate fetal growth.

The pattern of response of fetal leptin concentrations to dexamethasone treatment (decreased in dexamethasone-treated dams) was the opposite of those of the dams (increased in dexamethasone-treated dams). Thus fetal leptin concentrations do not reflect maternal leptin concentrations (or vice versa). In contrast, maternal dexamethasone treatment decreased both placental leptin expression and fetal leptin concentration. Placenta is a tissue of ‘fetal’ rather than maternal
Early growth retardation and leptin physiology

We are grateful to the Wellcome Trust (060965/Z/00) and the British Heart Foundation (FS/97079) for financial support. M L L was a recipient of a British Heart Foundation Studentship.

References
Leptin is not Gavrilova O, Barr V, Marcus-Samuels B & Reitman M. Hyper-
ontogeny of leptin in human fetuses and newborns: effect of


222 Gavrilova O, Barr V, Marcus-Samuels B & Reitman M. Hyper-


233 Levitt NS, Lindsay RS, Holmes MC & Seckl JR. Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology 1996 64 412–418.


Lindsay RS, Lindsay RM, Waddell BJ & Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996 39 1299–1305.


Received 18 October 2000
Accepted 15 June 2001